CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...

A gene-editing therapy led to durable changes in serum transthyretin levels among people with hereditary transthyretin ...

CRISPR Therapeutics has developed SyNTase editing, a proprietary, next-generation, site-specific gene correction platform.

The report provides a comprehensive analysis of the genome editing market, focusing on technologies like CRISPR-Cas, TALEN, ...

MB-111 is a potential first-in-class, single-dose in vivo CRISPR gene editing therapy for persistent chylomicronemiaOral presentation highlights safe, robust, and durable reduction of apoC-III and ...

With several disease-modifying therapies available for transthyretin amyloid cardiomyopathy (ATTR-CM) -- and more waiting in ...

The entire rationale behind this multi-pronged screening was the discovery of checkpoints or regulators that are critically involved in inducing suppression in NK cells under these diverse negative ...

MB-111 is a potential first-in-class, single-dose in vivo CRISPR gene editing therapy for persistent chylomicronemia Oral presentation highlights safe, robust, and durable reduction of apoC-III ...

CRISPR Therapeutics (CRSP) announced the acceptance of an abstract for oral presentation at the European Society of Gene and Cell Therapy, ESGCT, ...

Dr. Yeon Soo Kim, a postdoctoral fellow in Dr. Andrew Hsieh’s lab at Fred Hutch, has won a NIH Pathway to Independence Award ...

The Department of Defense funds biomedical research to ensure military and pandemic preparedness. This includes mRNA vaccine ...

Ark Invest bought shares of Alibaba, Intellia Therapeutics, and Baidu on Monday. Alibaba and Baidu are surging Chinese ...